Winter Meeting 2011 - The Pathological Society of Great Britain ...

Detailed Programme – Thursday 6 January 2011
Presenter = P · Abstract numbers are shown in bold and square brackets eg [S123]
radiology is essential, as is thorough sampling of the tumour bed. However, there is huge variation in the literature
as to what constitutes adequate sampling and in the way neoadjuvant specimens are reported between labs. In
addition, traditional histological factors such as tumour growth pattern and histological grade can be altered by
chemotherapy, and their validity in this context remains to be determined. Issues in the handling and reporting
of neoadjuvant specimens will be discussed, including grading of response and the use of sentinel lymph node
biopsy in this setting. Along with the emergence of new technologies and molecular diagnostic techniques, accurate
detailed macroscopic and histological assessment remains of vital importance in patient management and in
guiding future research.
11.30–12.00 [S3] Prospects in Glioma Diagnosis and Treatment
P Prof VP Collins
University of Cambridge, Dept. of Pathology, Addenbrooke’s Hospital, Cambridge, United Kingdom
Over the last 25 years we have learnt a considerable amount about the genetic abnormalities found in the common
brain tumours of man. Some of the findings have provided diagnostic markers while others provide prognostic
information, therapy response indicators or even potential therapeutic targets. Many of the genes identified belong
to cellular pathways that are more or less well understood. The major pathways involved include those transmitting
signals from the external environment (signal transduction pathways) and those controlling the cell cycle and
apoptosis. While the pattern of genetic abnormalities found may be distinct to a particular tumour, the pathways
disrupted by these genetic abnormalities are often the same as found in tumours of other organs. As a consequence
quite a number of targeted therapies produced for the more common malignancies may be applicable to brain
tumours. The problems targeting lesions behind the blood brain barrier will be briefly summarized and the various
pathways identified to date, and potentially targetable, in the common paediatric and adult brain tumours, will be
reviewed.
Cloisters
12.00–13.00 Lunch / Poster viewing / Trade Exhibition
Cloisters
13.00–15.00 Poster viewing and Chairman’s Rounds
CATEGORY
POSTER NUMBERS
Autopsy & Forensic P1 1
Breast
P2–P17 2 (Note: P6 withdrawn)
Cardiovascular/Pulmonary P18–P20 1
Cellular/Molecular Pathology P21–P27 6
Education & Audit
P28–P40³
Endocrine P41 1
Experimental Tumour Pathology P42 6
Gastrointestinal
P43–P57 4 (Note: P46 withdrawn)
Genitourinary/Renal P58–P62 5
Gynaecological P63–P64 5
Head & Neck P65–P66 5
Hepatobiliary/Pancreas P67–P70 4
Lymphoreticular P71–P74 7
Neonatal/Paediatric P75–P76 7
Osteoarticular/Soft Tissue P77–P82 7
Skin P83–P87 1
Technical Advances P88–P90 6
Chair:
¹ Dr EW Benbow, Manchester; Dr N Kirkham, Newcastle; Dr AJ Marker, Cambridge
² Dr R Liebmann, Kent; Dr E Provenzano, Cambridge
³ Dr Dr JWM Chow, London; Prof AH Wyllie, Cambridge
4
Prof M Pignatelli, Bristol; Dr SE Davies, Cambridge
5
Prof JE Martin, London; Dr MJ Arends, Cambridge; Dr TR Helliwell, Liverpool
6
Prof M Ilyas, Nottingham; Dr MJ Arends, Cambridge; Prof GI Murray, Aberdeen
7
Dr RJ Byers, Manchester; Dr F Jessop, Cambridge; Dr P Ramani, Bristol
Scientific Programme | Winter Meeting (199 th ) 6 – 7 January 2011 | Visit our website: www.pathsoc.org
11